N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

BOULDER, Colo., March 12, 2014 /PRNewswire/ — N30 Pharmaceuticals, Inc. (“N30 Pharma”) announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). Continue reading N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

CF and MRSA Clinical Trial by Savara Pharmaceutical

CLINICAL TRIAL
Are you a CF patient with persistent MRSA lung infection? If so, you may be interested in a Phase 2 clinical trial designed to evaluate the safety and efficacy of AeroVanc (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic Continue reading CF and MRSA Clinical Trial by Savara Pharmaceutical

New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements

The vast majority of Cystic Fibrosis treatments currently approved by the Food and Drug Administration focus on managing and curtailing symptoms of the disease rather than treating its underlying causes. However, a new pharma report from GBI Research Continue reading New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements

Phase 3 Trial from Vertex Studying Ivacaftor in R117H Mutated Cystic Fibrosis Shows Promise in Patients 18+

Completion of Phase 3 Clinical testing by Vertex for their investigational drug, Ivacaftor, in cystic fibrosis (CF) patients who have the R117H mutation, has revealed mixed results. Although Ivacaftor is approved to treat patients with cystic fibrosis and Continue reading Phase 3 Trial from Vertex Studying Ivacaftor in R117H Mutated Cystic Fibrosis Shows Promise in Patients 18+

Galapagos receives EU2.9 million IWT grant for cystic fibrosis research

MECHELEN, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE) — Galapagos NV (Euronext: GLPG) announced today that it has been awarded a EUR2.9 million grant from the Flemish agency for Innovation by Science and Technology (IWT) for cystic fibrosis (CF) research. The goal of this 3-year project is to identify and progress multiple promising CF therapies towards pre-clinical candidates . Continue reading Galapagos receives EU2.9 million IWT grant for cystic fibrosis research

Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

http://www.4-traders.com/VERTEX-PHARMACEUTICALS-IN-11321/news/Vertex-Pharmaceuticals-Incorporated–Patent-Issued-for-Modulators-of-Cystic-Fibrosis-Transmembrane-17743040/

By a News Reporter-Staff News Editor at Diabetes Week — A patent by the inventors Yang, Xiaoqing (San Diego, CA); Hadida Ruah, Sara Sabina (La Jolla, CA); Grootenhuis, Peter Diederik Jan (San Diego, CA); Continue reading Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

MRSA trial now recruiting patients

A new phase II trial is currently recruiting cystic fibrosis (CF) patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection to determine the effectiveness, safety, and pharmacokinetics of a new investigational inhalable powder formulation of vancomycin called Continue reading MRSA trial now recruiting patients

Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements

Clinical trials are vital part of advancing treatments for CF patients. Fundraising is the genesis for new treatments because it allows researchers to create new treatments, but clinical trials are the bridge from a breakthrough in the lab to a new medicine actually being available on the open Continue reading Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements